OSI-774 in advanced Esophageal Cancer: A phase II study.

被引：0
|
作者：
Radovich, D [1 ]
Kelsen, D [1 ]
Shah, M [1 ]
Klimstra, D [1 ]
Gavin, SG [1 ]
Munoz, D [1 ]
Ilson, DH [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4077
引用
收藏
页码：332S / 332S
页数：1
相关论文
共 50 条
  • [21] Southwest oncology group phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced non-small cell lung cancer and a performance status of 2
    Hesketh, Paul J.
    Chansky, Kari
    Wozniak, Antoinette J.
    Hirsch, Fred R.
    Spreafico, Anna
    Moon, James.
    Mack, Philip C.
    Marchello, Benjamin T.
    Franklin, Wilbur A.
    Crowley, John J.
    Gandara, David R.
    JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (09) : 1026 - 1031
  • [22] Phase I and pharmacokinetic study of erlotinib (OSI-774) in combination with docetaxel in squamous cell carcinoma of the head and neck (SSCHN)
    Kraut, Eric H.
    Rhoades, Christopher
    Zhang, Yilong
    Cheng, Hao
    Aimiumu, Josephine
    Chen, Ping
    Lang, James
    Young, Donn C.
    Agrawal, Amit
    Dancey, Janet
    Chan, Kenneth K.
    Grever, Michael R.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (03) : 579 - 586
  • [23] Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC)
    Gatzemeier, U
    Pluzanska, A
    Szczesna, A
    Kaukel, E
    Roubec, J
    Brennscheidt, U
    De Rosa, F
    Mueller, B
    Von Pawel, J
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 619S - 619S
  • [24] Phase I and pharmacokinetic study of erlotinib (OSI-774) in combination with docetaxel in squamous cell carcinoma of the head and neck (SSCHN)
    Eric H. Kraut
    Christopher Rhoades
    Yilong Zhang
    Hao Cheng
    Josephine Aimiumu
    Ping Chen
    James Lang
    Donn C. Young
    Amit Agrawal
    Janet Dancey
    Kenneth K. Chan
    Michael R. Grever
    Cancer Chemotherapy and Pharmacology, 2011, 67 : 579 - 586
  • [25] A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva®, OSI-774) in patients with advanced solid tumors of epithelial origin
    M. Ranson
    H. Shaw
    J. Wolf
    M. Hamilton
    S. McCarthy
    E. Dean
    A. Reid
    I. Judson
    Cancer Chemotherapy and Pharmacology, 2010, 66 : 53 - 58
  • [26] A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva®, OSI-774) in patients with advanced solid tumors of epithelial origin
    Ranson, M.
    Shaw, H.
    Wolf, J.
    Hamilton, M.
    McCarthy, S.
    Dean, E.
    Reid, A.
    Judson, I.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (01) : 53 - 58
  • [27] OSI-774 (Tarceva) in patients (pts) with unresectable or metastatic hepatocellular carcinoma (HCC): A multi-center phase 2 consortium (P2C) study.
    Philip, PA
    Mahoney, MR
    Thomas, JP
    Pitot, HC
    Donehower, R
    Kim, GP
    Picus, J
    Fitch, TR
    Geyer, SM
    Erlichman, C
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6096S - 6096S
  • [28] Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients
    Malik, SN
    Siu, LL
    Rowinsky, EK
    DeGraffenried, L
    Hammond, LA
    Rizzo, L
    Bacus, S
    Brattain, MG
    Kreisberg, JI
    Hidalgo, M
    CLINICAL CANCER RESEARCH, 2003, 9 (07) : 2478 - 2486
  • [29] Durable disease stabilization and antitumor activity with OSI-774 in renal cell carcinoma: A phase II, pharmacokinetic (PK) and biological correlative study with FDG-PET imaging
    Beeram, M
    Rowinsky, EK
    Weiss, GR
    Syed, S
    Mita, A
    Patnaik, A
    Mita, M
    Goldston, M
    De Bono, JS
    Tolcher, AW
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 207S - 207S
  • [30] Phase II study of erlotinib (OSI 774) in women with recurrent or metastatic endometrial cancer: NCICCTG IND-148.
    Jasas, KV
    Fyles, A
    Elit, L
    Hoskins, PJ
    Biagi, J
    Dubuc-Lissoir, J
    Matthews, S
    Dancey, J
    Eisenhauer, E
    Oza, AM
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 453S - 453S
12345